Latest Nicox Sa EUR Ord (NICXF) Headlines Nic
Post# of 3
Posted On: 03/10/2014 7:00:13 PM
Latest Nicox Sa EUR Ord (NICXF) Headlines
Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
GlobeNewswire - Fri Feb 14, 12:34AM CST
Nicox S.A. (NYSE Euronext Paris: COX) today announced its decision to re-focus naproxcinod development efforts. Nicox has granted an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of naproxcinod and of next generation nitric oxide (NO)- donors outside the ophthalmology area. The evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the partner, to invest at the end of the evaluation period in naproxcinod and next generation NO-donors outside ophthalmology through an independent structure. Nicox will not pursue any other development activities or discussions with third parties related to naproxcinod.
Seborrhea - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/g2tt6p/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2013" report to their offering. 'Seborrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea. Scope - A snapshot of the global therapeutic scenario for Seborrhea. - A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Seborrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International, Inc. NicOx S.A. Xenon Pharmaceuticals Inc. Maruho Co., Ltd. Vyome Biosciences Pvt Ltd Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/g2tt6p/seborrhea About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
PR Newswire - Thu Jan 16, 4:59PM CST
Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjo(TM), an advanced diagnostic panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Nicox completes the acquisition of Eupharmed
Thomson Reuters ONE - Fri Dec 06, 12:30AM CST
Nicox completes the acquisition of Eupharmed
Glaucoma & DES Market 2019 Forecasts: India, China, Japan & Australia
M2 - Thu Nov 07, 4:46AM CST
RnRMarketResearch.com adds Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity research report to its store. This research provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications. Complete report is available at http://www.rnrmarketresearch.com/ophthalmolog...eport.html .
Diabetic Macular Edema - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Diabetic Macular Edema
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jcpdr7/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Lux Biosciences, Inc. - Novagali Pharma SA - Astellas Pharma Inc. - TheraKine Inc. - iCo Therapeutics Inc. - NicOx SA - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Foamix Ltd. - Molecular Partners AG - Senju Pharmaceutical Co., Ltd. - Pfenex Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Ampio Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jc...ic_macular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation
Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis
NiCOX FEATURED ARTICLE: Presentations at ARVO 2013 Annual Meeting
Marketwire - Mon May 13, 6:36AM CDT
NiCOX WEB NEWS: FEATURED ARTICLE
Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
GlobeNewswire - Fri Feb 14, 12:34AM CST
Nicox S.A. (NYSE Euronext Paris: COX) today announced its decision to re-focus naproxcinod development efforts. Nicox has granted an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of naproxcinod and of next generation nitric oxide (NO)- donors outside the ophthalmology area. The evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the partner, to invest at the end of the evaluation period in naproxcinod and next generation NO-donors outside ophthalmology through an independent structure. Nicox will not pursue any other development activities or discussions with third parties related to naproxcinod.
Seborrhea - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/g2tt6p/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2013" report to their offering. 'Seborrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea. Scope - A snapshot of the global therapeutic scenario for Seborrhea. - A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Seborrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International, Inc. NicOx S.A. Xenon Pharmaceuticals Inc. Maruho Co., Ltd. Vyome Biosciences Pvt Ltd Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/g2tt6p/seborrhea About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
PR Newswire - Thu Jan 16, 4:59PM CST
Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjo(TM), an advanced diagnostic panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Nicox completes the acquisition of Eupharmed
Thomson Reuters ONE - Fri Dec 06, 12:30AM CST
Nicox completes the acquisition of Eupharmed
Glaucoma & DES Market 2019 Forecasts: India, China, Japan & Australia
M2 - Thu Nov 07, 4:46AM CST
RnRMarketResearch.com adds Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity research report to its store. This research provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications. Complete report is available at http://www.rnrmarketresearch.com/ophthalmolog...eport.html .
Diabetic Macular Edema - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Diabetic Macular Edema
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jcpdr7/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Lux Biosciences, Inc. - Novagali Pharma SA - Astellas Pharma Inc. - TheraKine Inc. - iCo Therapeutics Inc. - NicOx SA - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Foamix Ltd. - Molecular Partners AG - Senju Pharmaceutical Co., Ltd. - Pfenex Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Ampio Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jc...ic_macular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation
Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis
NiCOX FEATURED ARTICLE: Presentations at ARVO 2013 Annual Meeting
Marketwire - Mon May 13, 6:36AM CDT
NiCOX WEB NEWS: FEATURED ARTICLE
(0)
(0)Nicox Sa Eur Ord (NICXF) Stock Research Links
Scroll down for more posts ▼